Skip to main content
. 2021 Jan 11;11(1):e041072. doi: 10.1136/bmjopen-2020-041072

Table 3.

Clinical characteristics based on sibling history of DM

No sibling history of DM (n=806) Sibling history of DM (n=88) P value
Basic characteristics
 Age (years) 49.09±14.29 56.05±9.86 <0.001
 Men (%) 555 (68.9) 42 (47.7% <0.001
 BMI (kg/m2) 25.69±3.86 24.49±3.48 0.011*
 WHR 0.95±0.07 0.94±0.06 0.059
 SBP (mm Hg) 134.99±18.26 132.89±18.87 0.413
 DBP (mm Hg) 83.88±12.79 83.84±12.21 0.992
 Drinking (%) 218 (27) 22 (25) 0.819
Laboratory data
 Hb (g/L) 137.87±19.98 135.17±18.47 0.109
 PLT (×109/L) 219.13±88.22 225.44±87.34 0.57
 FBG (mmol/L) 9.16±4.62 9.57±3.97 0.079
 HbA1C (%) 10.10±2.86 10.43±2.43 0.232
 Alb (g/L) 37.27±4.95 36.88±4.36 0.247
 TC (mmol/L) 4.62±1.44 4.70±1.45 0.786
 LDL (mmol/L) 2.86±1.04 2.99±0.88 0.196
 HDL (mmol/L) 0.98±0.30 0.99±0.24 0.366
 TG (mmol/L) 2.75±3.42 2.28±2.88 0.358
 sCre (µmol/L) 68.99±39.27 63.56±23.95 0.12
 HOMA2-IR (%) 1.45±1.38 1.31±0.86 0.639
 HOMA2-B (%) 52.37±51.80 37.81±27.09 0.062
Complications
 DKA 30 (3.7%) 5 (5.7%) 0.379
 HTN 314 (39.0%) 38 (43.2%) 0.491
Medications
 ACEI (%) 117 (14.5) 9 (10.2) 0.334
 ARB (%) 117 (14.5) 17 (19.3) 0.269
 Lipid-lowering agents (%) 506 (62.8) 58 (65.9) 0.642

HOMA2-B and HOMA2-IR were applied to estimate the function of β-cell and insulin resistance, respectively, which were calculated using fasting plasma glucose and C-peptide.

*Refers to p<0.05.

ACEI, ACE inhibitor; Alb, albumin; ARB, angiotensin receptor blocker; BMI, body mass index; DBP, diastolic blood pressure; DKA, diabetic keto acidosis; DM, diabetes mellitus; FBG, fasting blood glucose; Hb, haemoglobin; HbA1C, glycosylated haemoglobin; HDL, high-density lipoprotein; HOMA2-B, homoeostatic model assessment 2-B; HOMA2-IR, homoeostatic model assessment 2-insulin resistance; HTN, hypertension; LDL, low-density lipoprotein; PLT, platelet; SBP, systolic blood pressure; sCre, serum creatinine; TC, total cholesterol; TG, triglyceride; WHR, waist-to-hip ratio.